Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
BACKGROUND: Multiple low-cost biosimilars of bevacizumab are now available but their clinical efficacy has never been compared against the original (innovator) molecule in glioblastoma. The aim of the current analysis is to compare the overall survival (OS) in recurrent/progressive glioblastoma pati...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929766/ https://www.ncbi.nlm.nih.gov/pubmed/33680080 http://dx.doi.org/10.3332/ecancer.2021.1166 |